TransMedics Group, Inc. (TMDX)
NASDAQ: TMDX · IEX Real-Time Price · USD
73.94
-0.18 (-0.24%)
At close: Mar 28, 2024, 4:00 PM
75.29
+1.35 (1.83%)
After-hours: Mar 28, 2024, 7:48 PM EDT

TransMedics Group Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017
Cash & Equivalents
395.31201.6826.0825.0820.5920.7412.44
Short-Term Investments
0066.87101.0660.6012.73
Cash & Cash Equivalents
395.31201.6892.95126.1481.1920.7425.16
Cash Growth
96.01%116.97%-26.31%55.37%291.44%-17.57%-
Receivables
63.5827.615.936.866.563.440.93
Inventory
44.2420.6114.8611.9311.229.287.97
Other Current Assets
7.532.44.961.831.041.34-0.02
Total Current Assets
510.65252.29118.71146.7710034.7934.04
Property, Plant & Equipment
180.4924.3515.694.754.793.472.46
Goodwill and Intangibles
14.34000000
Other Long-Term Assets
0.560.50.50.510.513.890.51
Total Long-Term Assets
195.3924.8516.195.265.37.362.97
Total Assets
706.05277.15134.89152.03105.342.1637
Accounts Payable
12.723.346.651.217.254.723.52
Deferred Revenue
1.960.240.250.260.170.310.24
Current Debt
2.041.4400001.81
Other Current Liabilities
38.2218.6416.3410.418.77.535.34
Total Current Liabilities
54.9323.6623.2411.8816.1212.5510.9
Long-Term Debt
513.9166.1143.834.6634.1533.676.85
Other Long-Term Liabilities
0001.60.391.661.46
Total Long-Term Liabilities
513.9166.1143.836.2634.5435.338.31
Total Liabilities
568.8589.7767.0448.1450.6547.8819.21
Total Debt
515.9567.5643.834.6634.1533.678.65
Debt Growth
663.74%54.23%26.38%1.50%1.41%289.16%-
Retained Earnings
-503.71-478.68-442.45-398.23-369.48-335.94-312.18
Comprehensive Income
-0.2-0.23-0.19-0.1-0-0.1-0.15
Shareholders' Equity
137.2187.3867.85103.8954.65-192.24-168.72
Net Cash / Debt
-120.63134.1349.1591.4947.04-12.9316.51
Net Cash / Debt Growth
-172.89%-46.27%94.48%---
Net Cash Per Share
-3.714.541.783.703.31-9.523.55
Working Capital
455.72228.6395.47134.8983.8922.2423.14
Book Value Per Share
4.226.342.464.213.85-141.49-36.30
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).